“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive […]
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.